1 week Ago By ABMN Staff
Cullen Frost Bankers Inc. lowered its stake in shares of Bristol-Myers Squibb ( NYSE:BMY – Free Report ) by 76.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC).
The firm owned 38,956 shares of the biopharmaceutical company’s stock after selling 125,153 shares during the quarter. Cullen Frost Bankers Inc.’s holdings in Bristol-Myers Squibb were worth $1,618,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently modified their holdings of the company. ESL Trust Services LLC purchased a new position in shares of Bristol-Myers Squibb during the first quarter valued at about $27,000. Northwest Financial Advisors purchased a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at about $27,000.
LGT Financial Advisors LLC increased its position in shares of Bristol-Myers Squibb by 42.7% during the second quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 227 shares during the period.
Fairman Group LLC purchased a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at about $42,000. Finally, Redmont Wealth Advisors LLC purchased a new position in shares of Bristol-Myers Squibb during the first quarter valued at about $47,000. Hedge funds and other institutional investors own 76.
41% of the company’s stock. Wall Street Analysts Forecast Growth Several equities analysts recently issued reports on BMY shares. Jefferies Financial Group boosted their price target on shares of Bristol-Myers Squibb from $49.
00 to $51.00 and gave the company a “hold” rating in a research report on Wednesday, August 28th. StockNews.
com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. Barclays upped their price objective on shares of Bristol-Myers Squibb from $41.00 to $42.
00 and gave the stock an “underweight” rating in a report on Thursday, August 22nd. Cantor Fitzgerald restated a “neutral” rating and issued a $45.00 price objective on shares of Bristol-Myers Squibb in a report on Monday, July 22nd.
Finally, Deutsche Bank Aktiengesellschaft cut their price objective on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a report on Tuesday, July 23rd.
Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $54.
67. Bristol-Myers Squibb Stock Down 2.2 % Shares of Bristol-Myers Squibb stock opened at $48.
70 on Monday. The company has a market cap of $98.72 billion, a price-to-earnings ratio of -15.
71, a price-to-earnings-growth ratio of 12.92 and a beta of 0.46.
The company’s 50 day moving average is $45.95 and its 200 day moving average is $46.55.
Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $61.42.
The company has a quick ratio of 1.02, a current ratio of 1.16 and a debt-to-equity ratio of 2.
86. Bristol-Myers Squibb ( NYSE:BMY – Get Free Report ) last issued its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.
07 earnings per share for the quarter, beating analysts’ consensus estimates of $1.64 by $0.43.
The company had revenue of $12.20 billion for the quarter, compared to the consensus estimate of $11.54 billion.
Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%.
The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.
75 earnings per share. Research analysts anticipate that Bristol-Myers Squibb will post 0.77 EPS for the current year.
Bristol-Myers Squibb Announces Dividend The business also recently disclosed a quarterly dividend, which was paid on Thursday, August 1st. Investors of record on Friday, July 5th were given a dividend of $0.60 per share.
The ex-dividend date of this dividend was Friday, July 5th. This represents a $2.40 dividend on an annualized basis and a yield of 4.
93%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.
Bristol-Myers Squibb Profile ( Free Report ) Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Recommended Stories Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb ( NYSE:BMY – Free Report ). Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.
com's FREE daily email newsletter ..
